DEA Raises Quotas for Amphetamines and Other Medicines Immediately
Published Date: 11/10/2026
Notice
Summary
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
d,l‑Amphetamine Production Increase
If you take d,l-amphetamine medicines, the DEA raised the 2026 production limit from 24,234,443 grams to 31,654,915 grams, effective November 10, 2026. The agency says this increase is to address reported domestic shortages and let manufacturers ramp up production and maintain reserve stocks immediately.
d‑Amphetamine (for Sale) Quota Raised
If you use d-amphetamine (for sale) products, the DEA raised the 2026 production limit from 26,450,000 grams to 37,108,041 grams, effective November 10, 2026. The increase responds to FDA-identified shortages and higher domestic and global medical need so manufacturers can increase output and build reserve stocks.
Hydromorphone Quota Increased for Injectables
If you need hydromorphone injectable products, the DEA raised the 2026 production limit from 1,949,378 grams to 2,356,798 grams, effective November 10, 2026. The agency cites reported domestic shortages, a predicted 20.9 percent increase in domestic medical need for 2026, and a projected 142 percent increase in exports as reasons for the increase.
Methylphenidate (for Sale) Quota Raised
If you use methylphenidate products, the DEA raised the 2026 production limit from 58,283,000 grams to 69,502,651 grams, effective November 10, 2026. DEA based the increase on FDA reports of domestic shortages, a predicted 23.4 percent increase in domestic medical need for 2026, and predicted global consumption growth of 8.01 percent.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22717, Specific Listing for 3-Chloromethcathinone, A Currently Controlled Schedule I Substance
The DEA is officially listing 3-chloromethcathinone (3-CMC) as a Schedule I drug with its own code, making it clear this substance is illegal like its close cousin 4-CMC. This change starts November 6, 2026, and affects anyone handling or selling this drug, tightening control and enforcement. No new costs are expected, just clearer rules to keep things safe and straightforward.
2026-22555, Importer of Controlled Substances Application: Diamond Animal Health, Inc.
Diamond Animal Health, Inc. wants to become an official importer of a controlled drug called Pentobarbital, which is used in animal health. People who make or use these drugs can share their thoughts or ask for a hearing by December 7, 2026. This move could affect businesses handling these substances and involves careful government review but no direct costs mentioned yet.
Previous / Next Documents
Previous: 2026-22840, Notice of Removal of Designated Chinese Military Company
The Department of Defense has officially removed WuXi AppTec from the list of Chinese military companies operating in the U.S. This change follows a court order and means WuXi AppTec is no longer restricted under this designation—at least for now. Businesses and investors can expect updated rules starting immediately, but the company could be added back later if new reasons arise.
Next: 2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.